Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats - PubMed (original) (raw)
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
B S Reddy et al. Carcinogenesis. 1993 Aug.
Abstract
Epidemiologic studies suggest that sustained use of aspirin may reduce the risk of development of and mortality due to colon cancer. Previous preclinical studies have shown that several non-steroidal anti-inflammatory drugs act as potential chemopreventive agents in experimentally induced colon cancer models. The present study was designed to investigate the chemopreventive effect of 40 and 80% maximum tolerated dose (MTD) levels of aspirin administered in the diet on azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. The MTD of aspirin as determined in male F344 rats was 500 p.p.m. Beginning at 5 weeks of age, all animals were randomly divided into various experimental groups (48 rats/group) and fed one of the semipurified diets containing 0, 200 p.p.m. (40% MTD), or 400 ppm (80% MTD) of aspirin. Two weeks later, all animals (36 rats/group) except the vehicle-treated groups (12 rats/group) were administered s.c. injections of AOM at a dose level of 15 mg/kg body wt, once weekly for 2 weeks. All animals were continued on their respective dietary regimen for additional 52 weeks and necropsied. Histopathologic evaluation of colon tumors was performed by routine procedures. Basal levels and ex vivo production of colonic mucosal and tumor prostaglandin E2 (PGE2) were measured in all groups. The results indicate that daily oral administration of 200 and 400 p.p.m. aspirin significantly inhibited the incidence (% animals with tumors) and multiplicity (tumors/animal) of invasive adenocarcinomas of the colon as well as the size of adenocarcinomas. Colonic mucosal and tumor PGE2 levels (basal and ex vivo production) were significantly reduced in animals administered 200 and 400 p.p.m. aspirin. The results of this study support the epidemiologic evidence that ingestion of aspirin inhibits colon carcinogenesis. Although the precise mechanisms of aspirin-induced colon tumor inhibition remain to be determined, it is likely that the effect may be mediated through the modulation of prostaglandin synthesis.
Similar articles
- Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis(methylene)selenocyanate.
Reddy BS, Rivenson A, Kulkarni N, Upadhyaya P, el-Bayoumy K. Reddy BS, et al. Cancer Res. 1992 Oct 15;52(20):5635-40. Cancer Res. 1992. PMID: 1394188 - Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS. Rao CV, et al. Cancer Res. 1995 Apr 1;55(7):1464-72. Cancer Res. 1995. PMID: 7882354 - The signal pathways in azoxymethane-induced colon cancer and preventive implications.
Chen J, Huang XF. Chen J, et al. Cancer Biol Ther. 2009 Jul;8(14):1313-7. doi: 10.4161/cbt.8.14.8983. Epub 2009 Jul 11. Cancer Biol Ther. 2009. PMID: 19502780 Review. - Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventions.
Lao CD, Brenner DE. Lao CD, et al. Curr Treat Options Oncol. 2004 Oct;5(5):417-26. doi: 10.1007/s11864-004-0031-5. Curr Treat Options Oncol. 2004. PMID: 15341679 Review.
Cited by
- An Adaptive Bayesian Design for Personalized Dosing in a Cancer Prevention Trial.
Sen A, Zhao L, Djuric Z, Turgeon DK, Ruffin MT, Smith WL, Brenner DE, Normolle DP. Sen A, et al. Am J Prev Med. 2020 Oct;59(4):e167-e173. doi: 10.1016/j.amepre.2020.04.023. Am J Prev Med. 2020. PMID: 32951684 Free PMC article. Clinical Trial. - Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.
Mohammed A, Yarla NS, Madka V, Rao CV. Mohammed A, et al. Int J Mol Sci. 2018 Aug 8;19(8):2332. doi: 10.3390/ijms19082332. Int J Mol Sci. 2018. PMID: 30096840 Free PMC article. Review. - Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ, Offerhaus GJ, Polak M, Goodman SN, Zahurak ML, Hylind LM, Hamilton SR, Giardiello FM. Keller JJ, et al. Gut. 1999 Dec;45(6):822-8. doi: 10.1136/gut.45.6.822. Gut. 1999. PMID: 10562579 Free PMC article. Clinical Trial. - Bowel movement frequency and risk of colorectal cancer in a large cohort study of Japanese men and women.
Kojima M, Wakai K, Tokudome S, Tamakoshi K, Toyoshima H, Watanabe Y, Hayakawa N, Suzuki K, Hashimoto S, Ito Y, Tamakoshi A; JACC Study Group. Kojima M, et al. Br J Cancer. 2004 Apr 5;90(7):1397-401. doi: 10.1038/sj.bjc.6601735. Br J Cancer. 2004. PMID: 15054462 Free PMC article. - Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
Shpitz B, Klein E, Buklan G, Neufeld D, Nissan A, Freund HR, Grankin M, Bernheim J. Shpitz B, et al. Gut. 2003 Nov;52(11):1598-601. doi: 10.1136/gut.52.11.1598. Gut. 2003. PMID: 14570729 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources